Monoclonal antibodies that block binding of CD22 ligand to the receptor on mature B cells.

摘要

The present invention relates to a series of new monoclonal antibodies directed against CD22, a restricted B lineage Ig superfamily member serving as an adhesion receptor EXPRESSED BY LYMPHOCYTES B MATURE AND IS FOR ROLE IN REGULATING ACTIVATION B cell antibodies (mAbs) monoclonal SPECIFICALLY BLOCK ACCESSION (80-100%) erythrocyte and leukocyte COS cells with cDNA TRANFIXIONADAS CD22 AND ALSO IDENTIFYING A REGION OF THOSE OTHER THAN CD22 CD22 mAb DEFINED previously described. The invention also includes therapeutic compositions comprising therapeutically effective amounts of a polypeptide comprising the binder CD22 OR PORTION OF THE OR A polypeptide comprising FIRST TWO DOMAINS OF TYPE TERMINAL AMINO IG CD22, OR BINDER links PORTION OF HE. Antibodies and polypeptides of the invention are used in THERAPEUTIC METHODS FOR TREATING HUMANOSPARA slow or block CD22 FUNCTION ADHESIVE, PARTICULARLY IN autoimmune diseases.